The Law Offices of Frank R. Cruz announces an investigation of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On August 5, 2024, before market hours, Actinium issued a press release providing an update on the planned Biologics License Application (“BLA”) filing for its radiotherapy product, Iomab-B, revealing that the FDA had determined that “the analyses from the [Phase 3 “Sierra Trial”] do not adequately support a BLA filing for Iomab-B and requires an additional clinical study.”

On this news, Actinium’s stock price fell $3.69, or 59.8%, to close at $2.48 per share on August 5, 2024, thereby injuring investors.